With increased research funding and a streamlined FDA drug approval process, we believe we've entered the biotech “Golden Age" for investing in transformational life sciences companies. Read as Jared Gross, Head of Institutional Portfolio Strategy, explores life science investing in the latest Allocation Spotlight.
Read more
For more information, please email us or contact your J.P. Morgan client advisor.